SI2949658T1 - Peptides that specifically bind HGF receptor (cMet) and uses thereof - Google Patents

Peptides that specifically bind HGF receptor (cMet) and uses thereof

Info

Publication number
SI2949658T1
SI2949658T1 SI200432448T SI200432448T SI2949658T1 SI 2949658 T1 SI2949658 T1 SI 2949658T1 SI 200432448 T SI200432448 T SI 200432448T SI 200432448 T SI200432448 T SI 200432448T SI 2949658 T1 SI2949658 T1 SI 2949658T1
Authority
SI
Slovenia
Prior art keywords
cmet
peptides
specifically bind
hgf receptor
bind hgf
Prior art date
Application number
SI200432448T
Other languages
Slovenian (sl)
Inventor
Aaron K. Sato
Daniel T. Dransfield
Robert C. Ladner
Original Assignee
Dyax Corp.
Bracco Suisse Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp., Bracco Suisse Sa filed Critical Dyax Corp.
Publication of SI2949658T1 publication Critical patent/SI2949658T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
SI200432448T 2003-03-03 2004-03-03 Peptides that specifically bind HGF receptor (cMet) and uses thereof SI2949658T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45158803P 2003-03-03 2003-03-03
EP15157779.8A EP2949658B1 (en) 2003-03-03 2004-03-03 Peptides that specifically bind HGF receptor (cMet) and uses thereof

Publications (1)

Publication Number Publication Date
SI2949658T1 true SI2949658T1 (en) 2018-10-30

Family

ID=32962606

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200432448T SI2949658T1 (en) 2003-03-03 2004-03-03 Peptides that specifically bind HGF receptor (cMet) and uses thereof

Country Status (13)

Country Link
US (6) US20050214859A1 (en)
EP (4) EP2284180B1 (en)
JP (4) JP5466350B2 (en)
AU (2) AU2004217894B2 (en)
CA (1) CA2517939C (en)
CY (1) CY1120683T1 (en)
DK (2) DK2284180T3 (en)
ES (3) ES2692166T3 (en)
HU (1) HUE039154T2 (en)
PL (2) PL1944312T3 (en)
PT (1) PT2949658T (en)
SI (1) SI2949658T1 (en)
WO (1) WO2004078778A2 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003278807A1 (en) 2002-03-01 2004-08-13 Bracco International B.V. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
HUE039154T2 (en) * 2003-03-03 2018-12-28 Dyax Corp Peptides that specifically bind HGF receptor (cMet) and uses thereof
NO20034350D0 (en) * 2003-09-29 2003-09-29 Amersham Health As Optical imaging of colorectal cancer
US20060008844A1 (en) * 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
EP1810037B1 (en) 2004-10-20 2010-07-21 PEAS Institut AB Assessment of biological activity of hepatocyte growth factor (hgf)
US7910555B2 (en) 2006-07-07 2011-03-22 Washington State University Research Foundation C-Met receptor regulation by angiotensin IV (AT4 ) receptor ligands
US8236761B2 (en) 2006-07-07 2012-08-07 Washington State University Research Foundation C-Met receptor regulation by angiotensin IV (AT4) receptor ligands
WO2008094275A1 (en) * 2007-01-30 2008-08-07 New York University Peptides for treatment of conditions associated with nitric oxide
CN101848734B (en) * 2007-05-16 2013-08-28 通用电气医疗集团股份有限公司 Labelled IIGF binding peptides for imaging
GB0718957D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
GB0718967D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
GB0918321D0 (en) 2009-10-20 2009-12-02 Ge Healthcare As Cyclic peptide synthesis
CN102762984A (en) 2009-11-05 2012-10-31 弗吉尼亚大学专利基金会 Compositions and methods for detecting plectin-1 as a biomarker for cancer
GB201013808D0 (en) * 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
GB201103696D0 (en) * 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201116733D0 (en) 2011-09-28 2011-11-09 Ge Healthcare As Peptide margin imaging agents
GB201116862D0 (en) 2011-09-30 2011-11-09 Ge Healthcare As Infusion imaging method
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
WO2014074907A1 (en) * 2012-11-09 2014-05-15 Indi Molecular, Inc. C-met-specific capture agents, compositions, and methods of using and making
JP2016519108A (en) 2013-04-18 2016-06-30 アルモ・バイオサイエンシーズ・インコーポレイテッド Method for using interleukin-10 for the treatment of diseases and disorders
WO2014204816A2 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
US9393177B2 (en) 2013-08-20 2016-07-19 Anutra Medical, Inc. Cassette assembly for syringe fill system
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
WO2015065897A1 (en) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
KR20160079114A (en) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 Methods of using interleukin-10 for treating diseases and disorders
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
WO2016023896A1 (en) * 2014-08-11 2016-02-18 Miti Biosystems GmbH Enzyme fused to a leader for cyclic peptide display
WO2016049044A1 (en) * 2014-09-22 2016-03-31 National Health Research Institutes Use of 5-methoxytryptophan as diagnostic agent of inflammatory diseases
JP2017536098A (en) 2014-10-14 2017-12-07 アルモ・バイオサイエンシーズ・インコーポレイテッド Interleukin-15 composition and use thereof
WO2016064817A1 (en) 2014-10-22 2016-04-28 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
US20190307849A1 (en) 2015-05-29 2019-10-10 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
KR20210041137A (en) 2015-06-15 2021-04-14 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Methods and compositions for treating age-associated conditions
JP7053453B2 (en) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド How to use interleukin 10 to treat diseases and disorders
AU2017273857B2 (en) * 2016-06-01 2021-08-19 Athira Pharma, Inc. Compounds
WO2018022603A1 (en) 2016-07-25 2018-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of making 18f-labeled precursors and peptides, labeled c-met binding peptides, and methods of use thereof
CN109689679A (en) 2016-09-13 2019-04-26 第一三共株式会社 Platelet factor4 binding peptide
CN109789183A (en) * 2016-09-29 2019-05-21 Aebi有限公司 Therapeutic more targeting construcs and application thereof
CA3039530A1 (en) 2016-10-07 2018-04-12 Navidea Biopharmaceuticals, Inc. Compounds and methods for diagnosis and treatment of viral infections
GB201804835D0 (en) * 2018-03-26 2018-05-09 Ge Healthcare As Formulation and method of preparation
GB2598676A (en) 2019-06-14 2022-03-09 Edinburgh Molecular Imaging Ltd Compounds and methods of use
AU2020382621A1 (en) 2019-11-13 2022-06-02 Amunix Pharmaceuticals, Inc. Barcoded XTEN polypeptides and compositions thereof, and methods for making and using the same
JP7162853B1 (en) 2021-07-02 2022-10-31 ペプチスター株式会社 Method for analyzing carrier-bound peptides for liquid-phase peptide synthesis
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023225273A1 (en) 2022-05-20 2023-11-23 Navidea Biopharmaceuticals, Inc. Cd206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4131648A (en) 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4180646A (en) 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4391797A (en) 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4718433A (en) 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
DE3834705A1 (en) 1988-10-07 1990-04-12 Schering Ag ULTRASONIC CONTRASTING AGENTS FROM GAS BUBBLES AND MICROPARTICLES CONTAINING FATTY ACID
DE3313947A1 (en) 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen MICROPARTICLES AND GAS BUBBLES CONTAINING ULTRASONIC CONTRASTING AGENTS
DE3313946A1 (en) 1983-04-15 1984-10-18 Schering AG, 1000 Berlin und 4709 Bergkamen MICROPARTICLES AND GAS BUBBLES CONTAINING ULTRASONIC CONTRASTING AGENTS
US4900540A (en) 1983-06-20 1990-02-13 Trustees Of The University Of Massachusetts Lipisomes containing gas for ultrasound detection
US4899755A (en) 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
MX174467B (en) 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-TRISCARBOXIMETHYL-1,4,7,10-TETRAAZACICLODO DECAN SUBSTITUTE IN 1 AND ANALOG COMPOUNDS
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
IE61591B1 (en) 1987-12-29 1994-11-16 Molecular Biosystems Inc Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production
US4844882A (en) 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5118797A (en) 1989-08-28 1992-06-02 E. R. Squibb & Sons, Inc. Rhenium tris dioxime complexes
CA2065290C (en) 1989-08-28 2000-12-12 Randall B. Lauffer Hydroxy-aryl metal chelates for diagnostic nmr imaging
US5773024A (en) 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5230882A (en) 1989-12-22 1993-07-27 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5305757A (en) 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5123414A (en) 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5871959A (en) * 1989-12-27 1999-02-16 The United States Of America As Represented By The Department Of Health And Human Services Method of producing hepatocycte growth factor/scatter factor and related cell lines
CA2034042C (en) 1990-01-18 1999-08-17 Adrian D. Nunn Boronic acid adducts of rhenium dioxime and technetium-99m dioxime complexes containing a biochemically active group
US5556610A (en) 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
IN172208B (en) 1990-04-02 1993-05-01 Sint Sa
US5578292A (en) 1991-11-20 1996-11-26 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
US5183653A (en) 1990-04-13 1993-02-02 E. R. Squibb & Sons, Inc. Boronic acid adducts of metal dioxime complexes useful in labelling proteins and other amine-containing compounds
US5137928A (en) 1990-04-26 1992-08-11 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
AU636481B2 (en) 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
US5173298A (en) 1990-09-27 1992-12-22 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5849261A (en) 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
EP0570493B1 (en) 1991-02-08 2000-01-05 Diatide, Inc. TECHNETIUM-99m LABELED POLYPEPTIDES FOR IMAGING
DE69232718T2 (en) 1991-02-22 2003-04-03 American Cyanamid Co Identification of a human receptor tyrosine kinase gene
GB9106673D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
GB9106686D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
US5558857A (en) 1991-06-03 1996-09-24 Nycomed Imaging As Contrast agents
EP0593624B1 (en) 1991-07-05 1997-04-23 Nycomed Imaging As Improvements in or relating to contrast agents
US5808091A (en) 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
GB9200387D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200388D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200391D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5316921A (en) * 1992-05-18 1994-05-31 Genentech, Inc. Single-chain hepatocyte growth factor variants
CA2118012A1 (en) * 1992-05-18 1993-11-25 Paul J. Godowski Hepatocyte growth factor variants
AU693767B2 (en) * 1992-08-10 1998-07-09 Cambridge Neuroscience, Inc. Inhibitors of cell proliferation, their preparation and use
RO119721B1 (en) 1992-10-28 2005-02-28 Genentech Inc. Antagonists of vascular endotelial cell growth factor
US5608110A (en) 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
IL110185A (en) 1993-07-02 1999-05-09 Molecular Biosystems Inc Method for making encapsulated gas microspheres from heat denatured protein in the absence of oxygen gas
DE69408145T2 (en) 1993-07-19 1998-09-03 Resolution Pharm Inc HYDRAZINE WITH A N3S CONFIGURATION AS RADIONUCLEID CHELATORS
US5798091A (en) 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
US5574140A (en) 1993-09-03 1996-11-12 Resolution Pharmaceutical Inc. Hydrazino-type N2 S2 chelators
JPH10508284A (en) 1993-12-15 1998-08-18 ブラッコ リサーチ ソシエテ アノニム Ultrasound contrast medium, contrast agent and method containing this medium
GB9402867D0 (en) 1994-02-15 1994-04-06 Nycomed Imaging As Improvements in or relating to contrast agents
DK0751992T3 (en) 1994-03-08 2006-03-06 Human Genome Sciences Inc Karendothelial growth factor 2
JP2891647B2 (en) 1994-03-11 1999-05-17 株式会社日本触媒 Organic sulfide compound and method for producing the same
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US5582814A (en) 1994-04-15 1996-12-10 Metasyn, Inc. 1-(p-n-butylbenzyl) DTPA for magnetic resonance imaging
AU2263295A (en) 1994-04-20 1995-11-16 Nycomed Salutar, Inc. Contrast agents
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5662885A (en) 1994-07-22 1997-09-02 Resolution Pharmaceuticals Inc. Peptide derived radionuclide chelators
GB9417941D0 (en) 1994-09-06 1994-10-26 Nycomed Imaging As Improvements in or relating to contrast agents
US5556939A (en) 1994-10-13 1996-09-17 Merck Frosst Canada, Inc. TC or RE radionuclide labelled chelate, hexapeptide complexes useful for diagnostic or therapeutic applications
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6221839B1 (en) 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6333021B1 (en) 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
DE4445065A1 (en) 1994-12-07 1996-06-13 Diagnostikforschung Inst Methods for in-vivo diagnostics using NIR radiation
IL116328A (en) 1994-12-16 1999-09-22 Bracco Research Sa Frozen suspension of gas microbubbles in frozen aqueous carrier for use as contrast agent in ultrasonic imaging
TW319763B (en) 1995-02-01 1997-11-11 Epix Medical Inc
GB9502065D0 (en) 1995-02-02 1995-03-22 Nycomed Imaging As Contrast media
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
EP1444991A1 (en) 1995-06-07 2004-08-11 Imarx Pharmaceutical Corp. Novel targeted compositions for diagnostic and therapeutic use
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
ES2202469T5 (en) 1995-09-08 2011-06-06 Genentech, Inc. PROTEIN RELATED TO VEGF.
WO1997017442A1 (en) 1995-11-08 1997-05-15 Immunex Corporation Flk-1 binding protein
US5837680A (en) 1996-02-16 1998-11-17 Children's Medical Center Corporation Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis
WO1997029783A1 (en) 1996-02-19 1997-08-21 Nycomed Imaging A/S Improvements in or relating to contrast agents
DK0907379T3 (en) 1996-04-01 2004-08-16 Epix Medical Inc Bioactivated diagnostic imaging contrast agent
ES2316157T3 (en) 1996-08-02 2009-04-01 Ge Healthcare As IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS.
TW320761B (en) * 1996-10-03 1997-11-21 Mos Electronics Taiwan Inc Manufacturing method of high density DRAM with cylindrical stack capacitor
ATE381353T1 (en) 1996-10-21 2008-01-15 Ge Healthcare As IMPROVEMENTS IN OR TO CONTRAST AGENTS
WO1998018495A2 (en) 1996-10-28 1998-05-07 Marsden, John, Christopher Improvements in or relating to diagnostic/therapeutic agents
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
WO1998018498A2 (en) 1996-10-28 1998-05-07 Marsden, John, Christopher Improvements in or relating to diagnostic/therapeutic agents
ES2257771T3 (en) 1996-10-28 2006-08-01 Amersham Health As CONTRAST AGENTS.
WO1998018497A2 (en) 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
AU733495B2 (en) 1996-10-28 2001-05-17 Nycomed Imaging As Improvements in or relating to diagnostic/therapeutic agents
WO1998018501A2 (en) 1996-10-28 1998-05-07 Marsden, John, Christopher Improvements in or relating to diagnostic/therapeutic agents
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US5919967A (en) 1997-04-11 1999-07-06 Epix Medical, Inc. Process for synthesizing phosphodiesters
DE19717904A1 (en) 1997-04-23 1998-10-29 Diagnostikforschung Inst Acid-labile and enzymatically cleavable dye constructs for diagnostics with near infrared light and for therapy
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
US6245318B1 (en) 1997-05-27 2001-06-12 Mallinckrodt Inc. Selectively binding ultrasound contrast agents
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion Transdermal delivery system
GB9712525D0 (en) 1997-06-16 1997-08-20 Nycomed Imaging As Method
WO1998058053A1 (en) 1997-06-18 1998-12-23 Merck & Co., Inc. Human receptor tyrosine kinase, kdr
ES2206996T3 (en) 1997-10-02 2004-05-16 Epix Medical Inc METHOD OF FORMATION OF IMAGES FOR DIAGNOSIS WITH IMPROVED CONTRAST TO MONITOR INTERVENTION THERAPIES.
JP4312955B2 (en) 1997-12-09 2009-08-12 チルドレンズ・メディカル・センター・コーポレイション Peptide antagonists of vascular endothelial growth factor
US6165458A (en) 1997-12-26 2000-12-26 Pharmaderm Laboratories Ltd. Composition and method for dermal and transdermal administration of a cytokine
JP4772958B2 (en) 1998-02-09 2011-09-14 ブラッコ・リサーチ・ソシエテ・アノニム Delivery towards the target of biologically active media
CA2320339A1 (en) 1998-02-11 1999-08-19 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules
US20020136721A1 (en) * 1998-02-17 2002-09-26 Schwall Ralph H. Hepatocyte growth factor receptor antagonists and uses thereof
HUP0101468A2 (en) 1998-03-31 2001-08-28 Du Pont Pharmaceuticals Company Pharmaceuticals for the imaging of angiogenic disorders
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
AU1908000A (en) 1998-11-06 2000-05-29 Basf Aktiengesellschaft Inhibition of the formation of vascular hyperpermeability
US6312665B1 (en) 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
CA2364630A1 (en) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. 50 human secreted proteins
EP1169344A1 (en) * 1999-03-12 2002-01-09 Human Genome Sciences, Inc. 47 human secreted proteins
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US6294525B1 (en) 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
GB9928950D0 (en) 1999-12-07 2000-02-02 Metris Therapeutics Limited Binding protein
EP1248642A4 (en) 2000-01-18 2005-05-18 Ludwig Inst Cancer Res Vegf-d/vegf-c/vegf peptidomimetic inhibitor
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
EP1252177A1 (en) 2000-02-04 2002-10-30 Supratek Pharma, Inc. Ligand for vascular endothelial growth factor receptor
DE60131146T2 (en) 2000-02-25 2008-03-06 Ludwig Institute For Cancer Research MATERIALS AND METHODS CONTAINING HYBRID VASCULAR ENDOTHELIC GROWTH FACTORS DNA AND PROTEINS AND SCREENING METHOD FOR MODULATORS
US20010038842A1 (en) 2000-03-02 2001-11-08 Marc Achen Methods for treating various cancers expressing vascular endothelial growth factor D, for screening for a neoplastic disease and for maintaining vascularization of tissue
US20020102260A1 (en) 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
US6769080B2 (en) * 2000-03-09 2004-07-27 Texas Instruments Incorporated Scan circuit low power adapter with counter
AU2001249393A1 (en) 2000-03-22 2001-10-03 Glaxo Group Limited Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
US20010031485A1 (en) 2000-03-22 2001-10-18 Sibtech, Inc. Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
EP1268544A2 (en) 2000-03-31 2003-01-02 Institut Pasteur Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001259195A1 (en) 2000-04-28 2001-11-12 Glaxo Group Limited Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses
EP1278771A4 (en) 2000-05-03 2004-06-16 Ludwig Inst Cancer Res A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
KR100457350B1 (en) * 2000-06-01 2004-11-16 이경림 IgE-dependent histamine-releasing factor(HRF) receptor, HRF-binding peptides and nucleic acids encoding the same, and uses thereof
EP1166799A1 (en) 2000-06-28 2002-01-02 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II)
EP1166798A1 (en) 2000-06-23 2002-01-02 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use
MXPA02011897A (en) 2000-06-23 2003-04-22 Schering Ag Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii).
US7175844B2 (en) 2000-07-18 2007-02-13 Joslin Diabetes Center, Inc. Methods of modulating fibrosis
US20020091082A1 (en) 2000-09-13 2002-07-11 Aiello Lloyd P. Methods of modulating symptoms of hypertension
FR2814744B1 (en) * 2000-10-04 2002-11-29 Commissariat Energie Atomique CYCLOPEPTIDES, THEIR PREPARATION PROCESS AND THEIR USE AS ANGIOGENESIS INHIBITOR OR ACTIVATOR
US20030082103A1 (en) 2000-10-11 2003-05-01 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
CN1494552A (en) 2001-01-19 2004-05-05 ·��ά��֢�о�Ժ Flt 4 (VEGFR-3) as target for tumor imaging and anti-tumor therapy
EP1385862A4 (en) 2001-04-13 2005-03-02 Human Genome Sciences Inc Vascular endothelial growth factor 2
WO2003000842A2 (en) * 2001-06-04 2003-01-03 Curagen Corporation Novel proteins and nucleic acids encoding same
JP2005505260A (en) * 2001-06-22 2005-02-24 インサイト・ゲノミックス・インコーポレイテッド Protein modification and maintenance molecules
WO2003028643A2 (en) 2001-10-01 2003-04-10 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
US6766860B2 (en) * 2002-02-22 2004-07-27 Globalsantafe Corporation Multi-activity offshore drilling facility having a support for tubular string
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US20040033949A1 (en) 2002-05-06 2004-02-19 Genentech, Inc. Use of VEGF for treating bone defects
HUE039154T2 (en) * 2003-03-03 2018-12-28 Dyax Corp Peptides that specifically bind HGF receptor (cMet) and uses thereof
KR101323849B1 (en) * 2005-12-09 2013-11-07 브라코 스위스 에스.에이. Targeting vector-phospholipid conjugates
DK2250498T3 (en) * 2008-02-25 2013-02-04 Nestec Sa PHARMACEUTICAL CHOICES FOR BREAST CANCER THERAPY USING ANTIBODY-BASED ARRAYS
US9801473B2 (en) 2012-09-13 2017-10-31 Kids Ii, Inc. Play yard with removable liner
EP3020171B1 (en) 2013-07-12 2017-12-20 Telefonaktiebolaget LM Ericsson (publ) Method for enabling control of data packet flows belonging to different access technologies

Also Published As

Publication number Publication date
US20150218218A1 (en) 2015-08-06
EP2949658A2 (en) 2015-12-02
EP2949658A3 (en) 2016-01-13
EP2949658B1 (en) 2018-08-08
PL1944312T3 (en) 2012-12-31
JP5466350B2 (en) 2014-04-09
JP2011037872A (en) 2011-02-24
JP6216280B2 (en) 2017-10-18
JP2017019787A (en) 2017-01-26
US8044175B2 (en) 2011-10-25
ES2396368T3 (en) 2013-02-21
DK2949658T3 (en) 2018-10-01
EP2284180B1 (en) 2015-09-09
PT2949658T (en) 2018-10-18
US20100261875A1 (en) 2010-10-14
CY1120683T1 (en) 2019-12-11
US20050214859A1 (en) 2005-09-29
AU2004217894B2 (en) 2010-07-15
AU2010235865B2 (en) 2012-11-15
US20110311446A1 (en) 2011-12-22
WO2004078778A2 (en) 2004-09-16
DK2284180T3 (en) 2015-12-21
CA2517939A1 (en) 2004-09-16
JP2014159434A (en) 2014-09-04
EP1603935A4 (en) 2007-03-21
JP5876644B2 (en) 2016-03-02
JP6374913B2 (en) 2018-08-15
JP2007524598A (en) 2007-08-30
US20100260672A1 (en) 2010-10-14
ES2692166T3 (en) 2018-11-30
ES2557286T3 (en) 2016-01-25
US9845340B2 (en) 2017-12-19
EP1603935A2 (en) 2005-12-14
EP2284180A2 (en) 2011-02-16
HUE039154T2 (en) 2018-12-28
PL2949658T3 (en) 2018-11-30
US9000124B2 (en) 2015-04-07
AU2004217894A1 (en) 2004-09-16
AU2010235865A1 (en) 2010-11-11
WO2004078778A3 (en) 2004-11-18
CA2517939C (en) 2015-11-24
EP1944312B1 (en) 2012-06-27
US20120039802A1 (en) 2012-02-16
EP2284180A3 (en) 2011-10-05
EP1944312A1 (en) 2008-07-16

Similar Documents

Publication Publication Date Title
SI2949658T1 (en) Peptides that specifically bind HGF receptor (cMet) and uses thereof
IL183353A0 (en) Polypeptides that bind br3 and uses thereof
EP1722808A4 (en) Egf receptor epitode peptides and uses thereof
EP1636334A4 (en) Recombinant anti-cd30 antibodies and uses thereof
HK1091116A1 (en) Recombinant il-9 antibodies and uses thereof
IL200404A0 (en) 191P4D12(b) PROTEINS, POLYNUCLEOTIDES ENCODING THE SAME; ANTIBODIES BINDING THERETO AND USES THEREOF
EP1578432A4 (en) Hla binding peptides and their uses
EP1499352A4 (en) Recombinant anti-interleukin-9 antibodies
EP1746902A4 (en) Multi-lectin affinity chromatography and uses thereof
HK1089110A1 (en) Recombinant lubricin molecules and uses thereof
EP1835027A4 (en) Novel cancer antigen peptide and the use thereof
EP1829969A4 (en) Novel polypeptide and the use thereof
AU2003288809A8 (en) Peptides that bind of the vegfr-2
EP1614695A4 (en) Polypeptide
GB0324457D0 (en) Modified peptides and their uses
AU2003285892A8 (en) Bace binding peptides and uses thereof
HK1209049A1 (en) Survivin-derived peptides and use thereof
EP1699809A4 (en) Amniotic-derived peptide and uses thereof
GB0401303D0 (en) Polypeptide and uses thereof
GB0312990D0 (en) Peptides and uses thereof
GB0323193D0 (en) Peptides and uses thereof
GB0425731D0 (en) Isolated peptides and uses thereof
GB0321401D0 (en) Antibodies,polypeptides and uses thereof
GB0422110D0 (en) Recombinant proteins
IL149179A0 (en) FcyRII-BINDING PEPTIDES AND USES THEREOF